Sociedad Americana de Hirudoterapia

[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors]

Review published in G Ital Cardiol (Rome) (2006)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosPuccio D et al. · G Ital Cardiol (Rome), 2006

Abstract

The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsAntithrombinsAzetidinesBenzylaminesClinical Trials as TopicDrug Therapy, CombinationFibrinolytic AgentsHirudinsHumansPeptide FragmentsRecombinant ProteinsThromboembolism

Resumen

The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis.

Por qué esto importa para la hirudoterapia

This article discusses direct thrombin inhibitors (DTIs) as anticoagulants that bind thrombin and block its interaction with fibrinogen, listing recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and ximelagatran, argatroban, and dabigatran as members of this drug class. It notes advantages over other anticoagulants and that efficacy and safety are under evaluation in clinical trials, with few clinical indications currently available. The abstract identifies lepirudin and desirudin as recombinant hirudins but makes no mention of leeches, the leech secretome, or hirudotherapy. The connection to ASH's domain is limited to the abstract's identification of certain drugs as recombinant hirudins within a broader discussion of pharmaceutical anticoagulants.

Citación

[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors].

Puccio D et al. · G Ital Cardiol (Rome), 2006

DOIPubMed

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsClinical EvidenceClinical ApplicationsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.